Shenzhen, Guangdong, China | Fund Name | Location |
| Beacon Equity Partners | Boston, Massachusetts, United States |
| Floret Ventures | California, San Francisco, United States |
| Gemini Investments | England, London, United Kingdom |
| Hanaco Venture Capital | Israel, Tel Aviv, Tel Aviv District |
| Ikigai Asset Management | California, Marina Del Rey, United States |
| Iscal Holdings | Israel, Tel Aviv, Tel Aviv District |
| New Era Cap | New York, New York, United States |
| New Media Venture Partners | Arizona, Phoenix, United States |
| Nickelodeon | England, London, United Kingdom |
| North Sky Capital | Minneapolis, Minnesota, United States |
| Peritus Capital | Canada, Ontario, Toronto |
| Rabo Corporate Investments | The Netherlands, Utrecht, Utrecht |
| Shougang Group Co, Ltd. | Beijing, Beijing, China |
| Signify | Amsterdam, Noord-Holland, The Netherlands |
| Stichting DOEN | Amsterdam, Noord-Holland, The Netherlands |
| Two Sigma Private Investments | - |
| Ulitzka Venture Capital GmbH | Cologne, Germany, Nordrhein-Westfalen |
| Wheaton Precious Metals Corp | British Columbia, Canada, Vancouver |
| Zero Stage Capital | Boston, Massachusetts, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
RNAimmune | $27M | 29 Mar 2022 | Maryland, United States | ||
SparX Group | $30M | 31 Dec 2021 | - | ||
Yidaichu | $18M | 21 May 2019 | Dongcheng District, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
RNAimmune | $27M | 29 Mar 2022 | Maryland, United States | ||
SparX Group | $30M | 31 Dec 2021 | - | ||
Yidaichu | $18M | 21 May 2019 | Dongcheng District, Beijing, China |
